Navigation Links
Aviir Diagnostics Laboratory in Collaboration with Cause;ology Sponsors "Storyland," a Red Carpet Charity Extravaganza in Hollywood

IRVINE, Calif., March 26, 2012 /PRNewswire/ -- Aviir, a biotechnology company dedicated to the prevention of cardiovascular disease through innovative laboratory tests and Guard A Heart, a non-profit foundation committed to raising awareness about heart disease prevention, will sponsor Storyland, a Red Carpet Charity Extravaganza in Hollywood on March 16th.

The party will have a whimsical Dr. Seuss theme, as homage to the children the charity gala benefits. A portion of the proceeds will go to the L.A. based non-profit "Reading, Writing, its Exciting," a program which helps at-risk children learn to read and write.

"It is our privilege to work in collaboration with Caus;ology to help further childhood literacy for those most vulnerable," said Dr. Harrington, CEO of Aviir Diagnostic Laboratories. "Through our support of this event we hope to raise awareness on the importance of heart disease prevention. As many as one in three kids and teens are overweight, contributing to early onset heart disease. Education is key for this highly controllable disease, and reading and writing is the foundation of any education. We are excited to be fostering literacy for children through this fun event."

The gala will be held at the world famous RISE building at Hollywood and Highland and will include a celebrity host, open bar, gourmet catering, DJ EQ, aerial dancers, photo booths, decadent desserts and event gift bags.

Tickets for this event can be purchased at:

About Aviir

Aviir was founded in 2005 by cardiologists and scientists from the Stanford University School of Medicine to focus on discovery, development and commercialization of innovative diagnostic tests. The biotechnology company specializes in developing proprietary diagnostic tests that will assist in identifying patients that are truly at high risk for the development of a cardiac event. Aviir's proprietary MIRisk and TruRisk assessments objectively identify, by a simple blood draw, individuals who are at a high risk of a cardiac event over the next five years. Aviir's CLIA laboratory (Irvine, CA) complements these novel tests with a wide range of additional tests for risk assessment and therapeutic monitoring of cardiovascular disease and related metabolic disorders – including pharmacogenomic and genetic tests. The company has adopted a unique clinical laboratory service model to provide physicians better diagnostic tools that improve cardiovascular health of their patients. The company is privately owned and funded by leading life science venture capital firms. Please visit for more information.

About Guard A Heart

Guard A Heart is a non-profit foundation dedicated to raising awareness of heart disease prevention by spreading the word to guard your heart and save your life. Cardiovascular disease is the leading cause of death in the United States. If individuals know their risk and take the necessary steps, the good news is that most cardiovascular disease is preventable. Although heart disease is typically diagnosed in adulthood, its roots are often found in childhood. Compelling research has shown that plaque buildup in the arterial walls begins very early in life and progresses through increasing degrees of atherosclerosis. Intervention strategies and healthy lifestyle changes to reduce heart disease risk should begin in childhood when reversal of the process is easier, not later in life when the disease is more fully developed.  Guard a Heart Foundation provides funding for individuals who are unable to pay for cardiac risk assessments. Please visit for more information.

For media inquiries, please contact:
Dina Scaglione

Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Berg Diagnostics Receives CLIA Certification and Launches Novel Vitamin D Assay
2. Rubicon Genomics and Agendia Sign Agreement for Use of TransPLEX® Whole Genome RNA Amplification Technology With Symphony™ Cancer Diagnostics
3. The butterfly effect in nanotech medical diagnostics
4. Accelerate Brain Cancer Cure and Exosome Diagnostics Collaborate to Advance Clinical Studies of Exosome Biofluid Molecular Diagnostics Technology in Brain Cancer
5. EUR 1.0 Million Grant Awarded to Exosome Diagnostics and Ludwig Maximilian University from German Federal Ministry for Education and Research to Develop Biofluid-Derived Exosome Diagnostics
6. ZyGEM to Provide its Unique DNA and RNA Extraction Technology to Middle East Biomedical Innovator Saudi Diagnostics Ltd.
7. Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012
8. Quest Diagnostics STRATIFY JCV™ First FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in Multiple Sclerosis Patients
9. Boulder Diagnostics Licenses Novel Rapid Detection Technology for Homocysteine and Related Compounds from Portland State University
10. India In Vitro Diagnostics Market Outlook to 2017- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture
11. QIAGEN Gains Rights to Genomic Biomarkers for Lung, Brain and Other Cancers to Expand its Pipeline of Companion Diagnostics
Post Your Comments:
(Date:11/26/2015)... England , November 26, 2015 ... innovative medical device company specializing in imaging technologies, announced today ... European Commission as part of the Horizon 2020 European Union ... carry out a large-scale clinical trial in breast cancer. ... (Logo: , --> --> ...
(Date:11/25/2015)... and HOLLISTON, Mass. , Nov. 25, ... HART ), a biotechnology company developing bioengineered organ ... Jim McGorry will present at the LD Micro ... at 2:30 p.m. PT. The presentation will be webcast ... days. Management will also be available at the conference ...
(Date:11/25/2015)... 2015 The Global Genomics ... professional and in-depth study on the current state ... ) , The report ... definitions, classifications, applications and industry chain structure. The ... markets including development trends, competitive landscape analysis, and ...
(Date:11/24/2015)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. ... will provide a corporate overview. th Annual Oppenheimer ... p.m. ET/10:00 a.m. PT . Jim Mazzola , vice ... overview. --> th Annual Oppenheimer Healthcare Conference in ...
Breaking Biology Technology:
(Date:10/29/2015)... 29, 2015  Rubicon Genomics, Inc., today announced ... of its DNA library preparation products, including the ... ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been optimized ... NGS libraries for liquid biopsies--the analysis of cell-free ... applications in cancer and other conditions. Eurofins Scientific ...
(Date:10/29/2015)... OXFORD, Connecticut , October 29, 2015 /PRNewswire/ ... "Company"), a biometric authentication company focused on the ... Wocket® smart wallet announces that StackCommerce, a leading ... will be featuring the Wocket® smart wallet on ... NXTD ) ("NXT-ID" or the "Company"), a ...
(Date:10/27/2015)... 27, 2015 In the present market scenario, ... for various industry verticals such as banking, healthcare, defense, ... growing demand for secure & simplified access control and ... as hacking of bank accounts, misuse of users, , ... as PC,s, laptops, and smartphones are expected to provide ...
Breaking Biology News(10 mins):